PLEASANTON, Calif., Jan. 2, 2025
/PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer
in health technology, today announced the expansion of
its board of directors with the addition of Dr. Shaheen Wirk, a leader in healthcare dedicated
investment with a track record of success in medicine,
partnerships, and research.
With over 20 years of investment experience in public and
private life science companies, Dr. Wirk is the founder and Chief
Investment Officer of Palkon Capital Management, a healthcare
dedicated investment firm launched in partnership with Julian Robertson and Tiger Management. Formerly,
Dr. Wirk was a senior analyst at Bridger Capital. He is the founder
of the advisory firm Blue Cotinga and was an early employee at
MercuryMD, which was successfully acquired by the Thomson Corp. He
currently serves on several boards and associations including
Tvardi Therapeutics and the Duke
University School of Medicine's Medical Alumni Council, the
leadership group for the Medical Alumni Association.
"It's an exciting time for Movano in driving healthcare
innovation, and they are on the cusp of transforming the delivery
of healthcare data," said Dr. Wirk. "The recent FDA approval of the
EvieMED Ring allows Movano and its partners to remotely and
accurately collect patient-specific key data while enabling more
robust clinical development programs and the realization
of remote patient monitoring solutions. I am honored to
collaborate with Movano to achieve these goals."
Movano Health announced last month that it had received U.S.
Food and Drug Administration (FDA) 510(k) clearance for the pulse
oximeter in its EvieMED Ring. The clearance enables Movano
Health to pursue multi-billion dollar business opportunities for
health monitoring solutions needed for applications such as
clinical trials, post-clinical trial management, and remote patient
monitoring for both healthcare providers and payors. The company's
first product, the Evie Ring wellness device, is currently in
market and sold through www.eviering.com.
"We are at a critical juncture in the evolution of our
organization as we continue to innovate at the intersection of
consumer wearable and medical device," said John Mastrototaro, President and CEO of Movano
Health. "Dr. Wirk is a visionary in the healthcare space and has a
wealth of investment experience with both private and public
companies and we're excited to have him join the Movano Board of
Directors."
Dr. Wirk completed research training programs in oncology and
trauma surgery at the University of
Texas MD Anderson Cancer Center, Rabin Medical Center
through the National Institutes of Health Fogarty International
Center, and Duke University Medical
Center. Dr. Wirk earned his M.D., M.B.A., and B.S. degrees from
Duke University.
About Movano Health
Founded in 2018, Movano Inc.
(Nasdaq: MOVE) dba Movano Health is developing a suite of
purpose-driven healthcare solutions to bring medical-grade data to
the forefront of wearables. Featuring modern and flexible form
factors, Movano Health's devices offer an innovative approach to
delivering trusted data to both customers and enterprises,
capturing a comprehensive picture of an individual's health data
and uniquely translating it into personalized and intelligent
insights.
Movano Health's proprietary technologies and wearable medical
device solutions will soon enable the use of data as a tool to
proactively monitor and manage health outcomes across a number of
patient populations that exist in healthcare. For more information
on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains
forward-looking statements concerning our expectations,
anticipations, intentions, beliefs, or strategies regarding the
future. These forward-looking statements are based on assumptions
that we have made as of the date hereof and are subject to known
and unknown risks and uncertainties that could cause actual
results, conditions, and events to differ materially from those
anticipated. Therefore, you should not place undue reliance on
forward-looking statements. Examples of forward-looking statements
include, among others, statements we make regarding plans with
respect to the commercial launches of the Evie Ring and EvieMED;
our expectations regarding potential commercial opportunities;
planned cost-cutting initiatives; anticipated FDA clearance
decisions with respect to our products; expected future operating
results; product development and features, product releases,
clinical trials and regulatory initiatives; our strategies,
positioning and expectations for future events or performance.
Important factors that could cause actual results to differ
materially from those in the forward-looking statements are set
forth in our most recent Annual Report on Form 10-K and any
subsequent Quarterly Reports on Form 10-Q, and in our other reports
filed with the Securities and Exchange Commission, including under
the caption "Risk Factors." Any forward-looking statement in
this release speaks only as of the date of this release. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/movano-health-welcomes-dr-shaheen-wirk-to-its-board-of-directors-302340968.html
SOURCE Movano
